. Author manuscript; available in PMC: 2018 Apr 29.

Published in final edited form as: Genet Med. 2017 Oct 26;21(5):1224–1232. doi: 10.1038/gim.2017.181

Table 1.

Summary of dimensions from each domain of the analysis

	Domain
	Clinical utility and applicability	Economic utility and cost considerations	Policy development influences
*Dimensions*	The value message of preemptive pharmacogenetics	Recognition of potential downstream benefits…but concerns of sustainability	Preventive population health
	CPIC guidelines and actionability	Stratifying beneficiaries	The role of CMS and the FDA
	The appropriate demonstration of evidence for payers	The number needed to test (NNT)	Impact of current implementation projects
	Testing compared to standard practice of medication use